Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03118492|
Recruitment Status : Recruiting
First Posted : April 18, 2017
Last Update Posted : August 16, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Secondary Myelofibrosis||Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Fludarabine Biological: Glycosylated Recombinant Human G-CSF AVI-014 Other: Laboratory Biomarker Analysis Drug: Melphalan Drug: Mycophenolate Mofetil Drug: Tacrolimus Radiation: Total-Body Irradiation||Phase 1|
I. To evaluate the safety and tolerability of reduced-intensity (fludarabine/melphalan) haploidentical hematopoietic cell transplantation (Haplo-HCT) followed by post-transplant cyclophosphamide (PTCy) in patients with advanced myelofibrosis (MF), as assessed by the evaluation of toxicities, including type, frequency, severity, attribution, time course and duration.
I. To summarize and evaluate hematologic (neutrophil and platelet) recovery. II. To evaluate and describe cytokine release syndrome (CRS) post haploidentical HCT in the setting of advanced myelofibrosis, as assessed by grade, frequency, severity, duration and reversibility (outcome).
III. To estimate graft failure-free survival (GFS) at 100-days post-transplant. IV. To estimate overall survival (OS), progression-free survival (PFS) and cumulative incidence (CI) of relapse/progression, and non-relapse mortality (NRM) at 100-days, 1-year, and 2-year post transplant.
V. To estimate the cumulative incidence of acute graft-versus-host disease (GvHD), grade II-IV, at 100-days post-transplant (per Keystone Consensus modification of the Glucksberg criteria).
VI. To estimate the cumulative incidence of chronic GvHD at 1-year and 2-year post transplant (per National Institutes of Health [NIH] Consensus Criteria).
VII. To characterize the severity and extent of acute and chronic GvHD.
I. To conduct correlative studies and describe inflammatory cytokine levels and GVHD biomarker levels in plasma and T cell differentiation/functions in patients enrolled onto the trial.
Patients receive melphalan intravenously (IV) over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo total body irradiation (TBI) on day -1 and hematopoietic cell transplantation (HCT) on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then orally (PO) for 6 months followed by a taper, mycophenolate mofetil PO thrice daily (TID) until day 35, and glycosylated recombinant human G-CSF AVI-014 (G-CSF) IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed for up to 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis|
|Actual Study Start Date :||May 24, 2017|
|Estimated Primary Completion Date :||May 24, 2023|
|Estimated Study Completion Date :||May 24, 2023|
Experimental: Treatment (combination chemotherapy, TBI, HCT)
Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Other Name: Fluradosa
Biological: Glycosylated Recombinant Human G-CSF AVI-014
Other Name: AVI-014
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Given IV or PO
Radiation: Total-Body Irradiation
- Incidence of adverse events [ Time Frame: Up to 100 days post-hematopoietic cell transplantation (HCT) ]Assessed by Bearman Toxicity Scale and National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (CTCAE) 4.03. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study regimen and reversibility or outcome.
- Incidence of unacceptable toxicity [ Time Frame: Up to 2 years ]Assessed by Bearman Toxicity Scale and NCI CTCAE version 4.03. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study regimen and reversibility or outcome.
- Neutrophil recovery [ Time Frame: Up to 2 years ]Defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count of >= 500/uL after conditioning.
- Platelet recovery [ Time Frame: Up to 2 years ]Defined as the first day of a minimum of 3 measurements on different days that the patient has achieved a platelet count >= 20,000/uL and did not receive a platelet transfusion in the previous 7 days.
- Incidence of cytokine release syndrome (CRS) [ Time Frame: After haploidentical HCT, assessed up to 2 years ]Defined and graded per American Society for Transplantation and Cellular Therapy (ASTCT) criteria.
- Graft failure-free survival [ Time Frame: Time from start of protocol treatment/infusion of stem cell product to graft-failure, death (from any cause), or last contact, whichever occurs first, assessed up to 2 years ]Will be calculated using Kaplan-Meier product-limit method, 95% confidence intervals will be calculated.
- Overall survival [ Time Frame: Time from start of protocol treatment/infusion of stem cell product to death (from any cause), or last contact, whichever occurs first, assessed up to 36 months ]Will be calculated using Kaplan-Meier product-limit method, 95% confidence intervals will be calculated.
- Progression-free survival [ Time Frame: Time from start of protocol treatment/infusion of stem cell product to, relapse, progression, death (from any cause), or last contact, whichever occurs first, assessed up to 2 years ]Will be calculated using Kaplan-Meier product-limit method, 95% confidence intervals will be calculated.
- Cumulative incidence of relapse/progression [ Time Frame: Up to 2 years ]The cumulative incidence of relapse/progression will be estimated using the method described by Gooley et al. (1999).
- Non-relapse mortality (NRM) [ Time Frame: Up to 2 years ]The cumulative incidence of NRM will be estimated using the method described by Gooley et al. (1999).
- Cumulative incidence of acute graft versus host disease (GvHD) [ Time Frame: Up to day 100 post-HCT ]Assessed by Keystone Consensus criteria. Time to the first day of acute GvHD onset (of any grade) will be used to estimate the cumulative incidence.
- Cumulative incidence of chronic graft versus host disease GvHD [ Time Frame: Up to 2 years post-HCT ]Assessed by National Institutes of Health Consensus Criteria. Time to the first day of chronic GvHD onset (of any grade) will be used to estimate the cumulative incidence.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Diagnosis of primary of secondary myelofibrosis with transplant indication by Dynamic International Prognostic Scoring System (DIPSS)-plus (> intermediate-1)
- Patients >= age 50 must have a comorbidity score (hematopoietic cell transplant-comorbidity index [HCT-CI]) < 4 (Sorror)
- Patients can be in chronic phase (CP) with bone marrow (BM) blast count =< 15% as long as no evidence of disease acceleration per principal investigator (PI) and treating physician's opinion or after progression to acute myeloid leukemia (AML) and achieved =< 5% BM blasts (morphologic complete remission [CR] prior to transplant)
- Lack of an human leukocyte antigen (HLA) matched donor or need to proceed fast to transplantation when a patient does not have an immediately available matched unrelated donor (typed by high-resolution in the registry)
- Performance status >= 70% (Karnofsky); patients > 50 years should have adequate cognitive function; any concerns regarding cognitive function should be addressed by a geriatrician/neurologist
- Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/bilirubin =< 5 X upper limit of normal (ULN)
- Measured creatinine clearance > 60 mls/min
- Left ventricular ejection fraction (LVEF) >= 50%
- Corrected carbon monoxide diffusing capability (DLCOc) >= 50%
- No active infections
- Prior treatment with JAK2 inhibitor therapy is not excluded; a JAK2 inhibitor will need to be stopped 1-2 days prior to starting conditioning regimen
- DONOR: Documented informed consent per local, state and federal guidelines
DONOR: Genotypically haploidentical as determined by HLA typing
- Preferably a non-maternal HLA haploidentical relative due to data of high incidence of graft failure with use of maternal HLA haploidentical cells
- Eligible donors include biological parents, siblings or half-siblings, children, or cousins in rare instances
- DONOR: Absence of pre-existing donor-specific anti-HLA antibodies (DSA) in the recipient; Patients with pre-existing DSA could undergo desensitization per City of Hope (COH) standard operating procedures [SOP] and should have DSA < MFI of 2000 prior to conditioning at discretion of PI
DONOR: Infectious disease screening performed within 30 days prior to stem cell mobilization per federal guidelines and is:
- Seronegative for HIV 1+2 antibody (Ab) and/or HIV polymerase chain reaction (PCR), human T-cell leukemia virus (HTLV) I/II Ab, hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (HBcAb), hepatitis C virus (HCV) Ab
- Negative rapid plasma reagin (RPR) for syphilis
- DONOR: Women of childbearing potential (WOCBP): Urine pregnancy testing performed within 7 days prior to stem cell mobilization
- DONOR: Is approved and completed evaluation prior to recipient initiation of the preparative regimen per institutional guidelines
- Evidence of severe portal hypertension with evidence of decompensation either with bleeding varices, large volume ascites, or hepatic encephalopathy
In a bone marrow biopsy 4 weeks prior to start of conditioning on study:
- > 15% bone marrow blasts at transplant if no history of AML and per PI and treating physician's opinion of disease acceleration
- > 5% if had previous progression to AML
- Human immunodeficiency virus (HIV) positive; active hepatitis B or C
- Patients with active infections; the PI is the final arbiter of the eligibility
- Patients with evidence of severe pulmonary hypertension by echocardiogram and confirmed by a subsequent right side cardiac catheterization pre-enrollment
- Liver cirrhosis
- Prior central nervous system (CNS) involvement by tumor cells
- History of another primary malignancy that has not been in remission for at least 3 years (the following are exempt from the 3-year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and cervical or breast carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)
- Positive beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
- Noncompliance - inability or unwillingness to comply with medical recommendations regarding therapy or follow-up, including smoking tobacco
- DONOR: Has undergone solid organ, stem cell, bone marrow or blood transplantation
- DONOR: Receiving any investigational agents, or concurrent biological, chemotherapy, immunosuppression or radiation therapy
- DONOR: Active infection
- DONOR: Thrombocytopenia < 150,000 cells /mm^3 at baseline evaluation
- DONOR: Sero-positive for HIV-1 & 2 antibody, HTLV-I & II antibody, hepatitis B virus (HBV) and HCV
- DONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis
- DONOR: Factors which place the donor at increased risk for complications from leukapheresis or G-CSF therapy
- DONOR: WOCBP: Pregnant or =< 6 months breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118492
|United States, California|
|City of Hope Comprehensive Cancer Center||Recruiting|
|Duarte, California, United States, 91010|
|Contact: Monzr M. Al Malki 626-256-4673 ext 62405 firstname.lastname@example.org|
|Principal Investigator: Monzr M. Al Malki|
|Principal Investigator:||Monzr M Al Malki||City of Hope Comprehensive Cancer Center|
|Responsible Party:||City of Hope Medical Center|
|Other Study ID Numbers:||
NCI-2017-00613 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
16420 ( Other Identifier: City of Hope Medical Center )
P30CA033572 ( U.S. NIH Grant/Contract )
|First Posted:||April 18, 2017 Key Record Dates|
|Last Update Posted:||August 16, 2022|
|Last Verified:||August 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Bone Marrow Diseases
Nitrogen Mustard Compounds
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action